At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
cediranib maleate +1 moredrug
Likely dose
cediranib maleate 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer
In Brief
A Phase 2 clinical trial evaluating cediranib maleate and laboratory biomarker analysis for Recurrent Fallopian Tube Cancer and 2 related conditions. Completed, enrolled 74 participants across 28 sites in 2 countries.
Detailed Summary
This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2006
Enrollment StartApr 2006
Primary CompletionJun 2010
Study CompletionJan 2018
TodayJul 2026
First PostedJan 18, 2006
Enrollment StartApr 1, 2006
Primary CompletionJun 1, 2010
Study CompletionJan 15, 2018
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 20.5 years ago
Interventions
cediranib maleatedrug
30mg given PO, daily
laboratory biomarker analysisother
Correlative studies